CA3077694A1 - Methods and compositions for inhibiting adam10 biological activities - Google Patents
Methods and compositions for inhibiting adam10 biological activities Download PDFInfo
- Publication number
- CA3077694A1 CA3077694A1 CA3077694A CA3077694A CA3077694A1 CA 3077694 A1 CA3077694 A1 CA 3077694A1 CA 3077694 A CA3077694 A CA 3077694A CA 3077694 A CA3077694 A CA 3077694A CA 3077694 A1 CA3077694 A1 CA 3077694A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- seq
- adam10
- modulating peptide
- positions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24081—ADAM10 endopeptidase (3.4.24.81)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762566580P | 2017-10-02 | 2017-10-02 | |
| US62/566,580 | 2017-10-02 | ||
| US201762589842P | 2017-11-22 | 2017-11-22 | |
| US62/589,842 | 2017-11-22 | ||
| PCT/US2018/053938 WO2019070685A1 (en) | 2017-10-02 | 2018-10-02 | METHODS AND COMPOSITIONS FOR INHIBITING BIOLOGICAL ACTIVITIES OF ADAM10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3077694A1 true CA3077694A1 (en) | 2019-04-11 |
Family
ID=65995419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3077694A Pending CA3077694A1 (en) | 2017-10-02 | 2018-10-02 | Methods and compositions for inhibiting adam10 biological activities |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20190345473A1 (https=) |
| EP (1) | EP3691671A4 (https=) |
| JP (2) | JP7448219B2 (https=) |
| AU (1) | AU2018345601B2 (https=) |
| CA (1) | CA3077694A1 (https=) |
| IL (1) | IL273725A (https=) |
| MX (1) | MX2020004218A (https=) |
| WO (1) | WO2019070685A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3094136A1 (en) | 2018-01-31 | 2019-08-08 | Verra Therapeutics LLC | Methods and compositions for inhibiting adam9 biological activities |
| WO2020227714A1 (en) * | 2019-05-09 | 2020-11-12 | Verra Therapeutics, Llc | Methods and compositions for inhibiting adam8 biological activities |
| JP2025507975A (ja) * | 2022-03-08 | 2025-03-21 | ノバ サウスイースタン ユニバーシティー | ディスインテグリンおよびメタロプロテアーゼ１０（ａｄａｍ１０）の酵素・基質選択的エキソサイト阻害剤を用いた関節リウマチ（ｒａ）の処置方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004024089A2 (en) | 2002-09-11 | 2004-03-25 | Sloan-Kettering Institute For Cancer Research | Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing |
| AU2004240630B2 (en) * | 2003-05-15 | 2010-10-07 | Trustees Of Tufts College | Stable analogs of peptide and polypeptide therapeutics |
| AU2006210589B2 (en) | 2005-02-02 | 2011-12-08 | Macrogenics West, Inc. | ADAM-9 modulators |
| EP1896580A2 (en) | 2005-04-07 | 2008-03-12 | Novartis Vaccines and Diagnostics, Inc. | Adam10 in cancer diagnosis, detection and treatment |
| US7638301B2 (en) * | 2006-08-28 | 2009-12-29 | Biozyme, Inc. | Prodomain modulators of ADAM 10 |
| US20090285840A1 (en) | 2008-04-29 | 2009-11-19 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Methods for treating pathological neovascularization |
| US8079782B1 (en) | 2008-05-16 | 2011-12-20 | Hilfiker William K | Semi-extensible steel soil reinforcements for mechanically stabilized embankments |
| US9150865B2 (en) | 2010-11-09 | 2015-10-06 | The University Of Chicago | Role of ADAM10 and its relevance to disease and therapeutics |
| WO2012088105A2 (en) * | 2010-12-20 | 2012-06-28 | Biozyme Inc. | Methods and compositions for predicting disease status in cancer |
| AU2015213481A1 (en) | 2014-02-04 | 2016-08-25 | Ludwig Institute For Cancer Research Ltd | Anti-Metalloprotease antibody for diagnosis and treatment of cancers |
-
2018
- 2018-10-02 WO PCT/US2018/053938 patent/WO2019070685A1/en not_active Ceased
- 2018-10-02 MX MX2020004218A patent/MX2020004218A/es unknown
- 2018-10-02 EP EP18865159.0A patent/EP3691671A4/en active Pending
- 2018-10-02 US US16/149,764 patent/US20190345473A1/en not_active Abandoned
- 2018-10-02 AU AU2018345601A patent/AU2018345601B2/en active Active
- 2018-10-02 CA CA3077694A patent/CA3077694A1/en active Pending
- 2018-10-02 JP JP2020520057A patent/JP7448219B2/ja active Active
-
2020
- 2020-03-31 IL IL273725A patent/IL273725A/en unknown
-
2022
- 2022-05-19 US US17/748,163 patent/US12297469B2/en active Active
-
2023
- 2023-11-01 JP JP2023187803A patent/JP2024012470A/ja active Pending
-
2025
- 2025-03-06 US US19/072,106 patent/US20250207119A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7448219B2 (ja) | 2024-03-12 |
| JP2021500321A (ja) | 2021-01-07 |
| JP2024012470A (ja) | 2024-01-30 |
| US20230203468A1 (en) | 2023-06-29 |
| MX2020004218A (es) | 2020-11-11 |
| AU2018345601B2 (en) | 2025-05-15 |
| EP3691671A4 (en) | 2022-01-19 |
| AU2018345601A1 (en) | 2020-05-21 |
| EP3691671A1 (en) | 2020-08-12 |
| US12297469B2 (en) | 2025-05-13 |
| WO2019070685A1 (en) | 2019-04-11 |
| US20190345473A1 (en) | 2019-11-14 |
| US20250207119A1 (en) | 2025-06-26 |
| IL273725A (en) | 2020-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250207119A1 (en) | Methods and compositions for inhibiting adam10 biological activities | |
| US20250188434A1 (en) | Methods and compositions for inhibiting adam9 biological activities | |
| US9260707B2 (en) | Compounds for inhibition of MMP13-substrate interactions and methods of use thereof to treat osteoarthritis and cartilage degeneration | |
| CN110944677B (zh) | 局部组合物及用途 | |
| CN108697766A (zh) | C型钠尿肽变体在治疗骨关节炎中的用途 | |
| JP2019056013A (ja) | ヒト成長ホルモン類似体を用いた小児成長ホルモン分泌不全症の治療 | |
| CN105722982A (zh) | 白介素-4受体结合融合蛋白及其应用 | |
| ES2372388T3 (es) | Complejos de factores de crecimiento y modulación de migración y crecimiento celular. | |
| CN105916875A (zh) | 用于慢性疼痛的多蛋白酶治疗剂 | |
| JP7214245B2 (ja) | 骨関節炎を予防または治療するための方法および薬剤 | |
| US20220331398A1 (en) | Methods and compositions for treatment of cartilage damage and arthritis | |
| JP7641025B2 (ja) | 神経損傷及び関連障害を治療するための方法 | |
| JP2022531937A (ja) | 筋萎縮性側索硬化症を治療するための方法と薬剤 | |
| AU2017277747A1 (en) | Peptides for the treatment of osteoarthritis | |
| US20110065189A1 (en) | Lacritin-Syndecan Interactions | |
| US20220213169A1 (en) | Methods and compositions for inhibiting adam8 biological activities | |
| US20200046811A1 (en) | Methods and compositions for modulating fgf23 levels | |
| HK40010872A (en) | Method and drug for preventing or treating osteoarthritis | |
| Wong | Implementation of Mechanistic Insights of ADAMs Activation Mechanism into the Design of Selective Endogenous-like ADAM17/TACE Inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220907 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240911 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240911 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240911 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250121 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250520 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250521 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250723 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250723 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250909 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250909 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST Effective date: 20251230 Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20251230 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251230 |